Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis.
hepatoma
intermediate-stage hepatocellular carcinoma
lenvatinib
progression-free survival
transarterial chemoembolization failure
tyrosine-kinase inhibitor
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
17
12
2019
accepted:
09
04
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
ppublish
Résumé
Tyrosine kinase inhibitors are considered for use in patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). The aim of the present retrospective study was to identify factors associated with progression-free survival (PFS) and to evaluate the indications for lenvatinib treatment in patients with intermediate-stage HCC refractory to TACE using a data-mining analysis. A total of 171 patients with intermediate-stage HCC refractory to TACE were included. All patients were classified into three groups according to their HCC treatment: Lenvatinib (n=45), sorafenib (n=53) and TACE (n=73) groups. PFS time was calculated using the Kaplan-Meier method and analyzed using a log-rank test. Factors associated with PFS time were evaluated using multivariate and decision-tree analyses. The median PFS time was 5.8, 3.2 and 2.4 months in the lenvatinib, sorafenib and TACE groups, respectively (P<0.001). In the Cox regression analysis, lenvatinib treatment and being within the up-to-seven criteria were identified as independent factors for PFS (lenvatinib, P<0.0001; within up-to-seven, P=0.001). The decision-tree analysis revealed that patients beyond the up-to-seven criteria, treated with lenvatinib and with albumin-bilirubin (ALBI) grade 1 had a longer PFS time (245.2±107.9 days) than patients beyond the up-to-seven criteria, treated with lenvatinib and with ALBI grade 2 (147.1±78.6 days). Additionally, lenvatinib was independently associated with longer PFS time in patients with intermediate-stage HCC refractory to TACE. Therefore, lenvatinib may be recommended for patients who have intermediate-stage HCC refractory to TACE, ALBI grade 1 and who are within the up-to-seven criteria.
Identifiants
pubmed: 32782543
doi: 10.3892/ol.2020.11758
pii: OL-0-0-11758
pmc: PMC7400966
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2257-2265Informations de copyright
Copyright: © Shimose et al.
Références
Cardiovasc Intervent Radiol. 2013 Jun;36(3):706-13
pubmed: 22996589
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Thyroid Res. 2014;2014:638747
pubmed: 25295214
Oncology. 2014;87 Suppl 1:22-31
pubmed: 25427730
Cancer Sci. 2018 Dec;109(12):3993-4002
pubmed: 30447042
Clin Drug Investig. 2015 Nov;35(11):751-9
pubmed: 26446004
Ann Oncol. 2009 Mar;20(3):460-4
pubmed: 19095776
Biochem Biophys Res Commun. 2019 May 21;513(1):1-7
pubmed: 30944079
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Cancer Invest. 2019;37(4-5):185-198
pubmed: 31006280
J Gastroenterol. 2014 May;49(5):932-40
pubmed: 23793266
J Gastroenterol. 2019 Jun;54(6):558-570
pubmed: 30788569
Am J Gastroenterol. 2008 Apr;103(4):914-21
pubmed: 18177453
Oncology. 2014;87(6):330-41
pubmed: 25227534
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Radiology. 2018 Dec;289(3):816-830
pubmed: 30251931
Br J Clin Pharmacol. 2016 Jun;81(6):1124-33
pubmed: 26879594
Dig Dis. 2017;35(6):602-610
pubmed: 29040999
Invest New Drugs. 2020 Feb;38(1):172-180
pubmed: 31172442
Hepatol Res. 2019 Aug;49(8):919-928
pubmed: 30969006
Hepatol Res. 2015 Jan;45(2):
pubmed: 25625806
Support Care Cancer. 2016 Aug;24(8):3669-76
pubmed: 27260018
Cancer Manag Res. 2018 May 04;10:1015-1025
pubmed: 29765249
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cancer Med. 2019 Jul;8(8):3719-3728
pubmed: 31127698
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Liver Cancer. 2015 Dec;4(4):253-62
pubmed: 26734579
J Hepatol. 2018 Aug;69(2):353-358
pubmed: 29704513
Liver Int. 2017 Dec;37(12):1861-1868
pubmed: 28581250
J Hepatol. 2019 Jun;70(6):1262-1277
pubmed: 30943423
Liver Transpl. 2009 Oct;15(10):1278-87
pubmed: 19790142
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Cancers (Basel). 2019 Jul 31;11(8):
pubmed: 31370183
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52
pubmed: 19908093
Liver Int. 2020 Apr;40(4):968-976
pubmed: 32064740
Vasc Cell. 2014 Sep 06;6:18
pubmed: 25197551
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284682
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89
pubmed: 16305721